Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has successfully completed an export of PEX010, the Company's botanical psilocybin drug candidate, to Israel. The shipment is believed to be the first botanical psilocybin to be exported to Israel. Hadassah University Hospital will study PEX010 in a clinical trial examining the effects of psilocybin for treatment-resist
Related Keywords
Israel , Canada , United States , Ronen Segman , Lisa Ranken , Instagram , Filament Health , Professor Of Psychiatry At Hadassah University Hospital , Hadassah University Hospital , Associate Professor , Hadassah University , Chief Operating Officer , Mental Health Conditions , Drug Candidate , Filament Health Corp , Clinical Trial , Psychedelic Drug , Ffects Of Psilocybin ,
comparemela.com © 2020. All Rights Reserved.